1. Kaltenthaler E, Tappenden P, Paisley S. Reviewing the evidence to inform the population of cost-effectiveness models within health technology assessments. Value in Health2013; 16(5):830-836.
  1. Essat M, Tappenden P, Kaltenthaler E, Paisley S. The identification and review of cost effectiveness model parameters: a qualitative study. HEDS Discussion Paper No. 13.08 2013.
  1. Kaltenthaler EC, Dickson R, Boland A, Carroll C, Fitzgerald P, Papaioannou D, Akehurst R. A qualitative study of manufacturers' submissions to the UK NICE single technology appraisal process. BMJ OPEN2012; 2(1) Article number ARTN e000562.
  1. Tappenden P, Paisley S, Kaltenthaler E. Reviewing the evidence to inform the population of cost- effectiveness models within health technology assessments. HEDS Discussion Paper No. 12.07 2012.
  1. Tappenden P, Paisley S, Kaltenthaler E. Reviewing the evidence used in cost-effectiveness models in health technology assessment: a qualitative investigation of current concerns and future research priorities. HEDS Discussion Paper No. 12.01 2012.
  1. Kaltenthaler E, Rathbone J, Tappenden P, Bessey A, Cantrell A. Issues In The Systematic Review Of Drugs For Rare Diseases: A Case Study of Eculizumab For aHUS. Value in Health. 2012; 15: A455-A455.
  1. Cooper CL, Hind D, Parry GD, Isaac CL, Dimairo M, O'Cathain A, Rose A, Freeman JV, Martin L, Kaltenthaler EC,et al. Computerised cognitive behavioural therapy for the treatment of depression in people with multiple sclerosis: external pilot trial. TRIALS2011;12Article number ARTN 259 14.
  1. Kaltenthaler E. The UK Nice Single Technology Appraisal Process: A Qualitative Study Based On Manufacturers' Submissions. Value in Health. 2011;14: A238-A238.
  1. Kaltenthaler E, Papaioannou D, Boland A, Dickson R. The National Institute for Health and Clinical Excellence Single Technology Appraisal Process: Lessons from the First 4 Years. Value in Health2011 (available online 8.09.11).
  1. Kaltenthaler E, Tappenden P, Paisley S, Squires H. NICE DSU Technical Support Document 13: Identifying and reviewing evidence to inform the conceptualisation and population of cost-effectiveness models; May 2011, NICE Decision Support Unit, ScHARR
  1. Carroll C, Kaltenthaler E, Fitzgerald P, Boland A, Dickson R. A thematic analysis of the strengths and weaknesses of manufacturers’ submissions to the NICE Single Technology Assessment (STA) process. . Health Policy 2011; 102 (2-3): 136-144.

12.Kaltenthaler E, Boland A, Carroll C, Dickson R, Fitzgerald P, Papaioannou D. Evidence Review Group approaches to the critical appraisal of manufacturer submissions for the NICE STA process: a mapping study and thematic analysis. Health Technol Assess 2011;15(22): 1-82.

13.Carroll C, Papaioannou D, Rees A, Kaltenthaler E. The clinical effectiveness and safety of prophylactic retinal interventions to reduce the risk of retinal detachment and subsequent vision loss in adults and children with Stickler syndrome: a systematic review Health Technol Assess 2011; 15(16):1–68.

  1. Carlton J & Kaltenthaler E. Amblyopia and quality of life: a systematic review. Eye 2011; 25: 403-413.
  1. Chilcott J, Tappenden P, Rawdin A, Johnson M, Kaltenthaler E, Papaioannou D, Shippam A. Avoiding and identifying errors in health technology assessment models. Health Technol Assess 2010; 14 (25): 1-135.
  1. Kaltenthaler E, Cavanagh K, McCrone P. Chapter 25 Evaluating the role of CCBT within mental health in. The Use of Technology in Mental Health: Application, Ethics and Practice edited by Anthony K, Nagel DM & Goss S, Charles C Thomas Publisher: Springfield, IL, 2010.
  1. Carlton J & Kaltenthaler E. Health related quality of life measures (HRQoL) in orthoptics: a systematic review. British Journal of Ophthalmology2011; 95: 325-330.
  1. Kaltenthaler E & Cavanagh K. Computerised Cognitive Behaviour Therapy and its uses. Progress in Neurology and Psychiatry 2010;14 (3): 22-29.
  1. Stevenson MD, Scope A, Sutcliffe PA, Booth A, Slade P, Parry G, Saxon D, Kaltenthaler Eand the Group cognitive-behavioural therapy for postnatal depression advisory group, Group cognitive-behavioural therapy for postnatal depression: a systematic review of clinical and cost effectiveness. Health Technol Assess 2010; 14 (44) 1-135.
  1. Chattopadhyay K, Haluszka J, Kaltenthaler E, A need of mothers' awareness and knowledge about oral rehydration salt (ORS) in the aim to reduce childhood diarrhoeal mortality in Kamala village, India, Environmental Medicine 2009; 12 (1): 103-108.

21.Ferriter M, Kaltenthaler E, Parry G, Beverley C Computerised Cognitive Behaviour Therapy for Phobias and Panic Disorder: A Systematic Review. Mental Health Review Journal 2009;13 (3): 24-31.

  1. Stevenson M, Scope A, Holmes M, Rees A, Kaltenthaler E. Rivaroxaban for the treatment of venous thromboembolism: a single technology appraisal. Health Technol Assess 2009; 13 supplement 3: 43-48.
  1. Ferriter M, Kaltenthaler E, Parry G, Beverley C. Computerised CBT: a review. Mental Health Today 2008; Oct: 30-31.
  1. Kaltenthaler E, Parry G, Beverley C, Ferriter M. Computerised cognitive behaviour therapy for Depression: a systematic review. British Journal of Psychiatry 2008; 193 (3): 181-184.
  1. Kaltenthaler E, Sutcliffe P, Parry G, Beverley C, Rees A, Ferriter M. The acceptability to patients of computerized cognitive behaviour therapy for depression: a systematic review. Psychological Medicine 2008; 38(11): 1521-1530.
  1. Kaltenthaler E, Tappenden P, Booth A, Akehurst RL. Comparing methods for full versus single technology appraisal: A case study of docetaxel and paclitaxel for early breast cancer. Health Policy 2008; 87(3): 389-400.
  1. Bravo-Vergel Y, Chilcott J, Kaltenthaler E, Walters S, Blakeborough A, Thomas SM. Economic evaluation of Magnetic Resonance Cholangiopancreatography compared to diagnositc endoscopic retrograde cholangiopancreatography for the investigation of biliary tree obstruction. International Journal of Surgery 2006; 4:12-19.
  1. Kaltenthaler E, Brazier JE, de Nigris E, et al. Computerised cognitive behaviour therapy for depression and anxiety update: a systematic review and economic evaluation. Health Technol Assess 2006; 10(33): 1-186.
  1. Kaltenthaler E, Walters S, Chilcott J, Blakeborough A, Bravo-Vergel Y, Thomas SM. Magnetic resonance Cholangiopancreatography compared to diagnostic endoscropic retrograde cholangiopancreatography for the diagnosis of biliary obstruction: Systematic Review. BMC Medical Imaging 2006; 6(9): 1-15.
  1. Tumur I, Kaltenthaler E, Ferriter M, Beverley C, Parry G. Computerised cognitive behaviour therapy for obsessive compulsive disorder: a systematic review. Psychotherapy and Psychosomatics 2006; 76(4): 196-202.
  1. Ward S, Kaltenthaler E, Cowan J, Marples M, Orr B, Seymour MT. The clinical and economic benefits of capecitabine and tegafur with uracil in metastatic colorectal cancer. British Journal of Cancer 2006; 95: 27-34.
  1. Kaltenthaler E, Parry G, Beverley C. Computerised Cognitive Behaviour Therapy: a Systematic Review. Behavioural and Cognitive Psychotherapy 2004; 32:31-55.
  1. Kaltenthaler E, Maheswaran R, Beverley C. Population Based Health Indexes: a Review. Health Policy 2004; 68: 245-255.
  1. Kaltenthaler E, Bravo-Vergel Y, Chilcott J, et al. A Systematic Review and Economic Evaluation of Magnetic Resonance Cholangiopancreatography Compared to Diagnostic Endoscopic Retrograde Cholangiopancreatography. Health Technol Assess 2003; 8(10): 1-102.
  1. Ward S, Kaltenthaler E, Cowan J, Brewer N. Clinical and cost-effectiveness of capecitabine and tegafur with uracil for the treatment of metastatic colorectal cancer: systematic review and economic evaluation. Health Technol Assess 2003; 7(32): 1-114.
  1. Akehurst RL, Brazier JE, Mathers N, l O'Keefe C, Kaltenthaler E, Morgan A; Platts M; Walters, SJ. Health-related quality of life and cost impacts of irritable bowel syndrome in a UK primary care setting. Pharmacoeconomics 2002; 20 (7): 455-462.
  1. Kaltenthaler E, Shackley P, Stevens K, Beverley C, Parry G, Chilcott J. A systematic review and economic evaluation of computerised cognitive behaviour therapy for depression and anxiety. Health Technol Assess 2002; 6(22): 1-107.
  1. Kaltenthaler E, Whitfield M, Walters S, Akehurst RL, Paisley S. UK, USA and Canada: how do their pressure ulcer prevalence and incidence data compare? Journal of Wound Care 2001;10 (1): 530-535.
  1. Akehurst RL, Kaltenthaler E. Treatment of irritable bowel syndrome: a review of randomised controlled trials. Gut 2001; 48(2): 272-282.
  1. Kaltenthaler E, McDonnell A, Peters J. Monitoring the care of lung cancer patients: linking audit and care pathways. Journal of Evaluation in Clinical Practice 2001; 7(1): 13-20.
  1. Whitfield MD, Kaltenthaler EC, Akehurst RL, Walters SJ, Paisley S.How effective are prevention strategies in reducing the prevalence of pressure ulcers? Journal of Wound Care 2000; 9(6):261-6.
  1. Kaltenthaler E, Morrell J, Booth A, Akehurst RL. The prevention and treatment of diabetic foot ulcers: a review of clinical effectiveness studies. Journal of Clinical Effectiveness 1998; 3(3): 99-104.
  1. Kaltenthaler E, Drasar BS. The study of hygiene behaviour in Botswana: a combination of qualitative and quantitative methods. Tropical Medicine and International Health 1996; 1(5): 690-698.
  1. Kaltenthaler E, Drasar BS. Understanding the hygiene behaviour in two villages in Botswana. Journal of Diarrhoeal Diseases Research 1996; 14(2): 75-80.
  1. Kaltenthaler E, Drasar BS, Potter C. The use of microbiology in the study of hygiene behaviour. Microbios 1996; 88: 35-43.
  1. Kaltenthaler E, Elsworth AM, Schweiger MS, Mara DD, Braunholtz DA. Faecal contamination on hands and environmental surfaces in Leeds primary schools. Epidemiology and Infection 1995; 115: 527-534.
  1. Kaltenthaler E, Pinfold JV. Microbiological methods for assessing handwashing practice in hygiene behaviour studies. Journal of Tropical Medicine and Hygiene 1995; 98: 101-106.
  1. Kaltenthaler E, Waterman R, Cross P. Faecal indicator bacteria on the hands and the effectiveness of hand washing in Zimbabwe. Journal of Tropical Medicine and Hygiene 1991; 94: 358-363.